{"title":"嗅觉功能检测对阿尔茨海默病和轻度认知障碍的诊断价值：系统综述和荟萃分析","authors":"Yuxuan Liu, Yunpeng Cao, Hongquan Wei","doi":"10.3389/fnagi.2025.1551939","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease (AD) is clinically classified into prodromal (asymptomatic), mild cognitive impairment (MCI) due to AD, and dementia due to AD. This study investigates the diagnostic value of olfactory function testing for AD and MCI.</p><p><strong>Methods: </strong>Systematic searches of PubMed, Web of Science, Cochrane, and EMBASE databases were conducted up to February 1, 2024. Methodological quality was assessed using the revised Quality Assessment of Diagnostic Accuracy Studies. Effect sizes were combined using a random-effects model (DerSimonian-Laird method), and statistical analyses were conducted using STATA 15.1 and Meta-Disc 1.4 software.</p><p><strong>Results: </strong>Twenty-five studies with 13,611 participants were included. For diagnosing AD, combined sensitivity (SE) was 0.79 (95% CI: 0.71-0.85), specificity (SP) was 0.78 (95% CI: 0.69-0.84), and AUC was 0.85 (95% CI: 0.82-0.88). For MCI, SE was 0.67 (95% CI: 0.54-0.78), SP was 0.79 (95% CI: 0.71-0.86), and AUC was 0.81 (95% CI: 0.77-0.84). Combined SE and SP for diagnosing AD and MCI were 0.58 (95% CI: 0.46-0.68) and 0.88 (95% CI: 0.78-0.93), with an AUC of 0.78 (95% CI: 0.74-0.82). SE and SP for AD or MCI were 0.83 (95% CI: 0.36-0.98) and 0.94 (95% CI: 0.82-0.98), with an AUC of 0.96 (95% CI: 0.94-0.98).</p><p><strong>Conclusion: </strong>This systematic review and meta-analysis reveal that olfactory function testing, as a simple, non-invasive, and cost-effective assessment method, demonstrates high diagnostic efficacy in the early identification of AD and MCI, showing promising clinical application.</p><p><strong>Systematic review registration: </strong>CRD42024520871.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1551939"},"PeriodicalIF":4.5000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119486/pdf/","citationCount":"0","resultStr":"{\"title\":\"Diagnostic value of olfactory function testing for Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis.\",\"authors\":\"Yuxuan Liu, Yunpeng Cao, Hongquan Wei\",\"doi\":\"10.3389/fnagi.2025.1551939\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Alzheimer's disease (AD) is clinically classified into prodromal (asymptomatic), mild cognitive impairment (MCI) due to AD, and dementia due to AD. This study investigates the diagnostic value of olfactory function testing for AD and MCI.</p><p><strong>Methods: </strong>Systematic searches of PubMed, Web of Science, Cochrane, and EMBASE databases were conducted up to February 1, 2024. Methodological quality was assessed using the revised Quality Assessment of Diagnostic Accuracy Studies. Effect sizes were combined using a random-effects model (DerSimonian-Laird method), and statistical analyses were conducted using STATA 15.1 and Meta-Disc 1.4 software.</p><p><strong>Results: </strong>Twenty-five studies with 13,611 participants were included. For diagnosing AD, combined sensitivity (SE) was 0.79 (95% CI: 0.71-0.85), specificity (SP) was 0.78 (95% CI: 0.69-0.84), and AUC was 0.85 (95% CI: 0.82-0.88). For MCI, SE was 0.67 (95% CI: 0.54-0.78), SP was 0.79 (95% CI: 0.71-0.86), and AUC was 0.81 (95% CI: 0.77-0.84). Combined SE and SP for diagnosing AD and MCI were 0.58 (95% CI: 0.46-0.68) and 0.88 (95% CI: 0.78-0.93), with an AUC of 0.78 (95% CI: 0.74-0.82). SE and SP for AD or MCI were 0.83 (95% CI: 0.36-0.98) and 0.94 (95% CI: 0.82-0.98), with an AUC of 0.96 (95% CI: 0.94-0.98).</p><p><strong>Conclusion: </strong>This systematic review and meta-analysis reveal that olfactory function testing, as a simple, non-invasive, and cost-effective assessment method, demonstrates high diagnostic efficacy in the early identification of AD and MCI, showing promising clinical application.</p><p><strong>Systematic review registration: </strong>CRD42024520871.</p>\",\"PeriodicalId\":12450,\"journal\":{\"name\":\"Frontiers in Aging Neuroscience\",\"volume\":\"17 \",\"pages\":\"1551939\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119486/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Aging Neuroscience\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fnagi.2025.1551939\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"GERIATRICS & GERONTOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Aging Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fnagi.2025.1551939","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
Diagnostic value of olfactory function testing for Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis.
Background: Alzheimer's disease (AD) is clinically classified into prodromal (asymptomatic), mild cognitive impairment (MCI) due to AD, and dementia due to AD. This study investigates the diagnostic value of olfactory function testing for AD and MCI.
Methods: Systematic searches of PubMed, Web of Science, Cochrane, and EMBASE databases were conducted up to February 1, 2024. Methodological quality was assessed using the revised Quality Assessment of Diagnostic Accuracy Studies. Effect sizes were combined using a random-effects model (DerSimonian-Laird method), and statistical analyses were conducted using STATA 15.1 and Meta-Disc 1.4 software.
Results: Twenty-five studies with 13,611 participants were included. For diagnosing AD, combined sensitivity (SE) was 0.79 (95% CI: 0.71-0.85), specificity (SP) was 0.78 (95% CI: 0.69-0.84), and AUC was 0.85 (95% CI: 0.82-0.88). For MCI, SE was 0.67 (95% CI: 0.54-0.78), SP was 0.79 (95% CI: 0.71-0.86), and AUC was 0.81 (95% CI: 0.77-0.84). Combined SE and SP for diagnosing AD and MCI were 0.58 (95% CI: 0.46-0.68) and 0.88 (95% CI: 0.78-0.93), with an AUC of 0.78 (95% CI: 0.74-0.82). SE and SP for AD or MCI were 0.83 (95% CI: 0.36-0.98) and 0.94 (95% CI: 0.82-0.98), with an AUC of 0.96 (95% CI: 0.94-0.98).
Conclusion: This systematic review and meta-analysis reveal that olfactory function testing, as a simple, non-invasive, and cost-effective assessment method, demonstrates high diagnostic efficacy in the early identification of AD and MCI, showing promising clinical application.
期刊介绍：
Frontiers in Aging Neuroscience is a leading journal in its field, publishing rigorously peer-reviewed research that advances our understanding of the mechanisms of Central Nervous System aging and age-related neural diseases. Specialty Chief Editor Thomas Wisniewski at the New York University School of Medicine is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
